BUFFALO, New York, April 14 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:

* * *

Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML

*

Roswell Park Comprehensive Cancer Center has launched an exclusive phase 1 clinical trial of a new chimeric antigen receptor (CAR) T-cell therapy for patients whose acute myeloid leukemia (AML) has . . .

Click here for more information about our products